The Endocannabinoid System as a Pharmacological Target for New Cancer Therapies
Despite the long history of cannabinoid use for medicinal and ritual purposes, an endogenous system of cannabinoid-controlled receptors, as well as their ligands and the enzymes that synthesise and degrade them, was only discovered in the 1990s. Since then, the endocannabinoid system has attracted w...
Guardado en:
Autores principales: | Robert Ramer, Felix Wittig, Burkhard Hinz |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e56174ea0d9348bf977bcef583c7187d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy
por: Wolfram Samlowski, et al.
Publicado: (2021) -
Immune modulation underpins the anti‐cancer activity of HDAC inhibitors
por: Wiktoria Blaszczak, et al.
Publicado: (2021) -
Sistema endocanabinoide y desarrollo de esteatosis hepática
por: Valenzuela,Carina, et al.
Publicado: (2014) -
New Therapeutic Strategy for Overcoming Multidrug Resistance in Cancer Cells with Pyrazolo[3,4-<i>d</i>]pyrimidine Tyrosine Kinase Inhibitors
por: Ana Podolski-Renić, et al.
Publicado: (2021) -
Upregulation of ERK-EGR1-heparanase axis by HDAC inhibitors provides targets for rational therapeutic intervention in synovial sarcoma
por: Cinzia Lanzi, et al.
Publicado: (2021)